Iratumumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameIratumumab
Drug Alias NameAntiCD30 antibody 5F11伊妥木单抗艾雷妥木单抗iratumumabumMonoclonal antibody 5F11 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, Large-Cell, AnaplasticHodgkin DiseaseLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedarex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLymphoma, Large-Cell, AnaplasticHodgkin DiseaseLymphoma

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG